Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19624858 | 0.90 | MAPT (0.52) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19545219 | 0.85 | MAPT (0.47) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19544658 | 0.77 | SCN9A (0.54) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19533676 | 0.77 | MAPT (0.62) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL25171648 | 0.77 | DUSP3 (0.56) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19805499 | 0.77 | KDM4E (0.49) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19544635 | 0.76 | NPSR1 (0.44) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19544721 | 0.72 | KDM4E (0.41) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL19544677 | 0.72 | PTGS2 (0.48) | MAPTSMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL19544883 | 0.72 | MAPT (0.44) | MAPTSMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246317-B1 | BTK INHIBITOR | HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) | 2023-02-22 | — | — | EP | disclosed |
| US-10662174-B2 | BTK inhibitor | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-05-26 | — | — | US | disclosed |
| EP-3246317-A1 | BTK INHIBITOR | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) | 2017-11-22 | — | — | EP | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313683-A1 | BTK INHIBITOR | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662174-B2 | BTK inhibitor | BTK, SYK, LYN | MAPT 418/4885SMN1; SMN2 4321/4885NPC1 3497/4885 |
| US-20170313683-A1 | BTK INHIBITOR | BTK, SYK, LYN | MAPT 418/4885SMN1; SMN2 4321/4885NPC1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.